ShapeTX

Ron Hause, SVP, Head of AI, describes Shape's approach, which is meant to be a one time treatment without introducing any inheritable DNA edits. biotechtv.com/post/shape-the…

How do you turn AI conversations into real progress? Next week at Benchtalk 2024, Generate’s @tharindi_h, PhD, joins @WillWeiss of @EliLillyandCo and @RonHause from @ShapeTx Inc. to discuss R&D’s toughest challenges. Don’t miss out—details here: benchtalk.benchling.com/boston24

We are pleased to welcome @DavidEpsteinRX and Todd Simpson to our board of directors. Their collective experience and expertise will be invaluable as we continue to advance our transformative science and drive growth. globenewswire.com/news-release/2…

Lessons from Shape Therapeutics: How to harness AI for R&D success benchling.com/blog/lessons-f…

Very exciting news from the recent ASGCT meeting! globenewswire.com/en/news-releas…

ShapeTX is once again taking over Union Square for #JPM2024! Look out for our kiosk ads throughout the area and visit ShapeTX.com to learn more about our work in engineering programmable medicines!

Heading to #JPM2024 next week? Meet with us onsite to learn more about our work creating programmable medicines with AI and RNA! Reach out via our contact form to set up a meeting: bit.ly/47mT99A

Calling all JPM Healthcare Conference attendees - join our VP of Process and Product Development, Ken Prentice as he moderates a panel on next-generation gene therapy for @GenScript's Biotech Global Forum on Jan 10 at 3:20 PM! Tickets available here: bit.ly/3S6yu4b

Our latest news update was an expansion of our partnership with @Roche. In December, @Roche added an additional target by utilizing our AI-powered RNAfix™ platform. A great way to close out 2023! Read about this and other ShapeTX news via @FierceBiotech bit.ly/3R1l4pw

We’ve enjoyed many great successes in 2023 thanks to our partners. In fall we announced our collaboration w/ Otsuka to apply our generative AI and AAVid™ capsid discovery platform w/ Otsuka’s expertise in ocular diseases to create novel treatment options bit.ly/3ZjG1je

Looking back on our proudest moments of 2023, our SVP and Head of AI Ron Hause's byline in @FastCompany is on our list! Read about how biotechs like ShapeTX are expanding the possibilities of generative AI for the next generation of drug development here: bit.ly/42XaFPC

As this year comes to a close, we're looking back on some of our proudest moments from 2023. In May, our CSO David Huss was named one of @endpts 20 under 40 in Biopharma. We're proud of David's ShapeTX accomplishments while also running 100+ mile races! bit.ly/48rrDbM

Our SVP and Head of AI Ron Hause leads a team using #generativeAI to develop programmable RNA medicines for disease treatment. What does that mean in practice? Check out Ron's Coworking feature in @etechbrew to learn more bit.ly/3uDWCmD

On the anniversary of ChatGPT's launch, @FastCompany asked asked AI leaders including our SVP and Head of AI Ron Hause how #generativeAI is changing drug development. Read their insights here: bit.ly/3RoUA2s

ICYMI - we've expanded our partnership with @Roche to add an additional target by utilizing our AI-powered RNAfix™ platform. Read the latest on this deal and our Otsuka deal from earlier this year via @FierceBiotech: bit.ly/3R1l4pw

We've expanded our work with @Roche to add a new target to our existing collaboration. For this partnership, we're conducting preclinical research to identify and deliver development candidates discovered by our AI-powered RNAfix™ platform: bit.ly/46DGwql

2023 was a meaningful year for the cell and gene therapeutics industry, and we were proud to announce our partnership with Otsuka. We look forward to continued industry growth in 2024: bit.ly/3ujAX2K

ShapeTX CTO Adrian Briggs has always been drawn to solving seemingly insurmountable scientific problems. Learn how Adrian's scientific journey has brought him to leading a team that is creating disruptive end-to-end gene therapies in his employee spotlight bit.ly/3ukpeAV

There's been a big milestone in the therapeutics community - we're thrilled to see the UK approval of the first CRISPR medicine, and we look forward to the day the first RNA editing therapy is approved for treating genetic diseases! bit.ly/40FterM

ShapeTX scientist Lina Bagepalli designs guide RNAs for efficient and specific RNA editing to correct genetic mutations that cause disease. See how Lina's scientific work mirrors her artistic process, finding the balance between control and experimentation bit.ly/3MfphnL